Tetrahydroisoquinoline-3-carboxylate based matrix-metalloproteinase inhibitors: Design, synthesis and structure-activity relationship

Bioorganic and Medicinal Chemistry

Volumn 10, Issue 11, 2002, Pages 3529-3544

  Matter, Hans ^a   Schudok, Manfred ^a   Schwab, Wilfried ^a   Thorwart, Werner ^a   Barbier, Denis ^a   Billen, G ^a   Haase, Burkhard ^a   Neises, Bernhard ^a   Weithmann, Klaus Ulrich ^a   Wollmann, Theo ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 CHLOROBIPHENYLETHANESULFONYL) 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBOXYLIC ACID; LIGAND; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; UNCLASSIFIED DRUG; ZINC ION;

ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CATALYSIS; CHIRALITY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; GEOMETRY; HYDROPHOBICITY; NEUTROPHIL; NONHUMAN; PROTEIN INTERACTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RABBIT; STRUCTURE ANALYSIS;

ANIMALS; BIOLOGICAL AVAILABILITY; COMPUTATIONAL BIOLOGY; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; INDICATORS AND REAGENTS; ISOQUINOLINES; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NEUTROPHILS; PROTEASE INHIBITORS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RABBITS; TETRAHYDROISOQUINOLINES;

ANIMALIA;

EID: 0036836679     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(02)00215-8     Document Type: Article

References (52)

1. (a) Woessner J.F. Jr. FASEB J. 5:1991;2145.
2. (b) Birkedal-Hansen H., Moore W.G.I., Bodden M.K., Windsor L.J., Birkedal-Hansen B., DeCarlo A., Engler J.A. Crit. Rev. Oral Biol. Med. 4:1993;197.
3. © Murphy G., Docherty A.J.P. A. J. Res. Cell. Mol. Biol. 7:1992;120.
4. (d) Matrisian L.M. Trends Genet. 6:1990;121.
5. Lohmander L.S., Hoerrner L.A., Lark M.W. Arthrit. Rheum. 36:1993;181.
6. Murphy G., Hembry R.M. J. Rheumatol. 19:1992;61.
7. Peress N., Perillo E., Zucker S. J. Neuropathol. Exp. Neurol. 54:1995;16.
8. Bode W., Reinemer P., Huber R., Kleine T., Schnierer S., Tschesche H. EMBO J. 13:1994;1263.
9. (a) Nishino, N.; Powers, J. C. Biochemistry 1979, 18, 4340.
10. (b) Powers, J. C.; Harper, J. W. In Proteinase Inhibitors; Barrett, A. J., Salvesen, G., Eds.; Elsevier: Amsterdam, New York, Oxford, 1986; p 219.
11. © Johnson, W. H.; Roberts, N. A.; Borkakoti, N. J. Enzyme Inhib. 1987, 2, 1.
12. Zask, A.; Levin, J. I.; Killar, L. M.; Skotnicki, J. S. Curr. Pharm. Design 1996, 2, 624.
13. Reinemer P., Grams F., Huber R., Kleine T., Schnierer S., Pieper M., Tschesche H., Bode W. FEBS Lett. 338:1994;227.
14. Stams T., Spurlino J.C., Smith D.L., Wahl R.C., Ho T.F., Qoronfleh M.W., Banks T.M., Rubin B. Nature Struct. Biol. 1:1994;119.
15. Grams F., Reinemer P., Powers J., Kleine T., Pieper M., Tschesche H., Huber R., Bode W. Eur. J. Biochem. 228:1995;830.
16. Grams F., Crimmin M., Hinnes L., Huxley P., Pieper M., Tschesche H., Bode W. Biochemistry. 34:1995;14012.
17. Betz M., Huxley P., Davies S.J., Mushtaq Y., Pieper M., Tschesche H., Bode W., Gomis-Rueth F.X. Eur. J. Biochem. 247:1997;356.
18. Schlechter I., Berger A. Biochem. Biophys. Res. Commun. 27:1967;157.
19. PDB-files from Protein Database (National Brookhaven Laboratories): 1MMB, 1MNC, 1KBC, 1JAN, 1JAO, 1JAP and 1JAQ (http://www.pdb.bnl.gov) Bernstein F.C., Koetzle T.F., Williams G.J.B., Meyer E.F., Brice M.D., Rodgers J.R., Kennard O., Shimanouchi T., Tasumi M. J. Mol. Biol. 112:1977;535.
20. Cramer R.D., Patterson D.E., Bunce J.E. J. Am. Chem. Soc. 110:1988;5959.
21. Clark M., Cramer R.D., Jones D.M., Patterson D.E., Simeroth P.E. Tetrahedron Comp. Methods. 3:1990;47.
22. 3D-QSAR in Drug Design. Theory, Methods and Applications. Kubinyi, H., Ed. ESCOM: Leiden, Netherlands, 1993.
23. Klebe G., Abraham U., Mietzner T. J. Med. Chem. 37:1994;4130.
24. Baroni M., Costantino G., Cruciani G., Riganelli D., Valigi R., Clementi S. Quant. Struct.-Act. Relat. 12:1993;9.
25. Matter H., Schwab W., Barbier D., Billen G., Haase B., Neises B., Schudok M., Thorwart W., Schreuder H., Brachvogel V., Lönze P., Weithmann K.-U. J. Med. Chem. 42:1999;1908.
26. Matter H., Schwab W. J. Med. Chem. 42:1999;4506.
27. Residue numbering follows pro HNC nomenclature Hasty K.A., Pourmotabbed T.F., Goldberg G.I., Thompson J.P., Spinella D.G., Stevens R.M., Mainardi C.L. J. Biol. Chem. 265:1990;11421.
28. Goodford P.J. J. Med. Chem. 28:1985;849.
29. Hodgson J. Bio/Technology. 13:1995;554.
30. Chapman K.T., Durette P.L., Caldwell C.G., Sperow K.M., Niedzwiecki L.M., Harrison R.K., Saphos C., Christen A.J., Olszewski J.M., Moore V.L., Maccoss M., Hagmann W.K. Bioorg. Med. Chem. Lett. 6:1996;803.
31. (a) Caldwell C.G., Sahoo S.P., Polo S.A., Eversole R.R., Lanza T.J., Mills S.G., Niedzwiecki L.M., Izquierdo-Martin M., Chang B.C., Harrison R.K., Kuo D.W., Lin T.Y., Stein R.L., Durette P.L., Hagmann W.K. Bioorg. Med. Chem. Lett. 6:1996;323.
32. (b) Chapman K.T., Wales J., Sahoo S.P., Niedzwiecki L.M., Izquierdo-Martin M., Chang B.C., Harrison R.K., Stein R.L., Hagmann W.K. Bioorg. Med. Chem. Lett. 6:1996;329.
33. © Beeley N.R.A., Ansell P.R.J., Docherty A.J.P. Curr. Opin. Ther. Pat. 4:1994;7.
34. Levy D.A., Lapierre F., Liang W., Ye W., Lange C.W., Li X., Grobelny D., Casabonne M., Tyrrell D., Holme K., Nadzan A., Galardy R.E. J. Med. Chem. 41:1998;199.
35. Burley S.K., Petsko G.A. Science. 229:1985;23.
36. (a) Jones, G.; Willett, P.; Glen, R. C. J. Comp.-Aided Mol. Des 1995, 9, 532.
37. (b) Implemented in: SYBYL Molecular Modelling Package, Version 6.4; Tripos: St. Louis, MO, USA, 1997.
38. Thorwart, W.; Schwab, W.; Schudok, M.; Haase, B.; Bartnik, E.; Weithmann, K. U. Ger. Offen CODEN: GWXXBX. DE 19542189 A1 970515. CAN 127:50547.
39. (a) Cox E.D., Cook J.M. Chem. Rev. 95:1995;1797.
40. (b) Lorsbach B.A., Kurth M.J. Chem. Rev. 99:1999;1549.
41. Schudok, M. European Patent Application 0878467.
42. Gavuzzo E., Pochetti G., Mazza F., Gallina C., Gorini B., D'Alessio S., Pieper M., Tschesche H., Tucker P.A. J. Med. Chem. 43:2000;3377.
43. 50* 100,000).
44. Artursson P., Palm K., Luthman K. Adv. Drug Deliv. Rev. 46:2001;27.
45. Caldwell G.W. Curr. Opin. Drug Discov. Dev. 3:2000;30.
46. t1/2β: terminal halflife; CMC: Carboxymethylcellulose; DONSS: Dioctylsulfosuccinate; Fluka 86139.
47. Begtrup M., Holm J. J. Chem. Soc., Perkin Trans. 2. 1981;503.
48. Weithmann K.U., Schlotte V., Jeske V., Seiffge D., Laber A., Haase B., Schleyerbach R. Inflamm. Res. 46:1997;246.
49. Knight C.G., Willenbrock F., Murphy G. FEBS Lett. 296:1992;263.
50. SYBYL Molecular Modeling Package, Versions 6.3, 6.4 and 6.5; Tripos: St. Louis, MO, USA, 1996-1998.
51. Clark M., Cramer R.D., Van Opdenbosch N. J. Comp. Chem. 10:1989;982.
52. Gasteiger J., Marsili M. Tetrahedron. 36:1980;3219.